Hepatitis C - Europe: More Direct-Acting Antivirals, More Controversy

Europe: More Direct-Acting Antivirals, More Controversy
By Guest Blogger | Published: September 2, 2014

Source

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in combination for the treatment of chronic infection in adults.

The company will now start negotiations with each of the national pricing and reimbursement authorities in the EU countries where it wants to launch the product—and those negotiations will be conducted amid the turbulence created by arguments over the price for Gilead’s Sovaldi (sofosbuvir).

For the full Applied Clinical Trials article by Peter O’Donnell, click here.

This entry was posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory and tagged Bristol Myers Squibb, Daklinza, directly-acting antiviral, EC, EU, Gilead, Sovaldi. Bookmark the permalink. Trackbacks are closed, but you can post a comment.

Weekend Reading: Evolution of Hepatitis C Virus Treatment

Evolution of Hepatitis C Virus Treatment

Good afternoon folks, welcome to this edition of weekend reading, we close out the month with a podcast from the August issue of Gastroenterology & Hepatology

Dr. Kuemmerle along with Dr. Fasiha Kanwal discuss SVR rates using first generation DAA therapies, current agents, and what we can expect in the future. In addition, access to treatment is examined with an emphasis on making HCV treatment more affordable to everyone.

Evolution of Hepatitis C Virus Treatment

  • An editorial in the August issue of CGH discusses changing treatment methods for Hepatitis C Virus infection over the last several years. Dr. Kuemmerle speaks to first author Dr. Fasiha Kanwal of Baylor College of Medicine.